EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4‐carrying women: An observational study

Ainara Jauregi-Zinkunegi iD, Carey E Gleason, Barbara Bendlin, Ozioma Okonkwo, Bruce P Hermann, Kaj Blennow, Henrik Zetterberg, Eef Hogervorst, Sterling C Johnson, Rebecca Langhough, Kimberly D Mueller, Davide Bruno

Alzheimer's & Dementia · 2025-02 · 21 (2)

DOI: 10.1002/alz.14456 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 09.01.2025. Verfasst von Ainara Jauregi-Zinkunegi und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Psychology, Liverpool John Moores University, Liverpool, UK. Hauptthemen laut MEDLINE: Apolipoprotein E4, Alzheimer Disease, Amyloid beta-Peptides, Menopause. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH-NIA, NIA NIH HHS, Liverpool John Moores University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Menopausal hormone therapy (MHT), along with the apolipoprotein E ( APOE ) ε4 allele, has been suggested as a possible risk factor for Alzheimer's disease (AD). However, the relationship between MHT and cerebrospinal fluid (CSF) biomarkers is unknown: we investigated this association, and whether APOE ε4 carrier status moderates it. METHODS In an observational study of 136 cognitively unimpaired female participants ( M age = 66.0; standard deviation = 6.3), we examined whether MHT use alone or in interaction with APOE ε4 carrier status was associated with CSF levels of phosphorylated tau (p‐tau), amyloid beta (Aβ)40, Aβ42, p‐tau/Aβ42, and Aβ42/40 ratios. RESULTS Significant interactions were found between APOE ε4 and MHT use for CSF biomarkers. APOE ε4 carriers who were MHT users showed worse levels of CSF p‐tau/Aβ42 and Aβ42/40 ratios than all other users and non‐users. DISCUSSION The presence of both APOE ε4 and MHT may be associated with elevated amyloid deposition and AD pathology in this sample of participants who demonstrated high familial AD risk. Highlights Significant interactions were found between apolipoprotein E ( APOE ) ε4 and menopausal hormone therapy (MHT) use for cerebrospinal fluid (CSF) phosphorylated tau (p‐tau)/amyloid beta (Aβ)42 and Aβ42/40 ratios. APOE ε4 carriers who were MHT users showed worse levels of CSF biomarkers than non‐users and non‐carriers, both users and non‐users. Younger age at MHT initiation was associated with worse levels of the p‐tau/Aβ42 and Aβ42/40 ratios in carriers only. The presence of both APOE ε4 carriage and MHT use may be associated with elevated amyloid deposition and AD pathology. Further studies with larger sample sizes are necessary to confirm the differences observed in the current study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein E4Alzheimer DiseaseAmyloid beta-PeptidesMenopauseEstrogen Replacement TherapyHumansFemaleBiomarkerstau ProteinsAgedMiddle AgedPeptide FragmentsHeterozygote

Stichwörter der Autor:innen

Alzheimer's diseaseapolipoprotein E ε4 allelebiomarkercerebrospinal fluidhormone therapymenopause

Substanzen

BiomarkersApolipoprotein E4Amyloid beta-Peptidestau ProteinsPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • School of Psychology, Liverpool John Moores University, Liverpool, UK.
  • Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA.
  • Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.

ORCID-Profile: Ainara Jauregi-Zinkunegi

Förderung

  • NIH-NIA
  • NIA NIH HHS
  • Liverpool John Moores University

Zitieren

APA

Jauregi-Zinkunegi, A., Gleason, C. E., Bendlin, B., Okonkwo, O., Hermann, B. P., Blennow, K., Zetterberg, H., Hogervorst, E., Johnson, S. C., Langhough, R., Mueller, K. D., & Bruno, D. (2025). Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4‐carrying women: An observational study. Alzheimer's & Dementia, 21(2). https://doi.org/10.1002/alz.14456

Vancouver

Jauregi-Zinkunegi A, Gleason CE, Bendlin B, Okonkwo O, Hermann BP, Blennow K, et al. Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4‐carrying women: An observational study. Alzheimer's & Dementia. 2025;21(2). doi:10.1002/alz.14456

BibTeX
@article{JauregiZinkunegi2025,
  author = {Jauregi-Zinkunegi, Ainara and Gleason, Carey E and Bendlin, Barbara and Okonkwo, Ozioma and Hermann, Bruce P and Blennow, Kaj and Zetterberg, Henrik and Hogervorst, Eef and Johnson, Sterling C and Langhough, Rebecca and Mueller, Kimberly D and Bruno, Davide},
  title = {Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4‐carrying women: An observational study},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {2},
  doi = {10.1002/alz.14456}
}
Kostenlos starten →